Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03887429 · ClinicalTrials.gov registry record · Phase 2
Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal
A Phase 2 study, sponsored by Promentis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT03887429: Completed Phase 2 study, sponsored by Promentis Pharmaceuticals.
NCT03887429 is a Phase 2 study that has completed, run by Promentis Pharmaceuticals. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03887429, a Phase 2 study, has completed, sponsored by Promentis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 or placebo when dosed for 5 days in adults with tobacco use disorder who voluntarily abstain from the use of cigarettes.
Primary Outcome
Endpoint assessed using the frequency of serious adverse events, adverse events leading to discontinuation, and adverse events judged to be related to study medication.
Interventions
- DRUG Placebos
- DRUG SXC-2023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-03-04 |
| Est. Completion | 2019-07-09 |
| Phase | Phase 2 |
What the finished NCT03887429 record still lists
NCT03887429 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03887429 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03887429 about?
NCT03887429 is a clinical study titled "Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal". The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 or placebo when dosed for 5 days in adults with tobacco use disorder who voluntarily abstain from the use of cigarettes.
What is the current status of trial NCT03887429?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2019-03-04. Estimated completion is 2019-07-09.
What interventions are being tested in trial NCT03887429?
The interventions under investigation include: Placebos (DRUG), SXC-2023 (DRUG).
Who is sponsoring clinical trial NCT03887429?
This trial is sponsored by Promentis Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03887429's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI